Androgen deprivation therapy associated with risk of alzheimer, dementia diagnoses in older men with prostate cancer

(JAMA Network) Data for 154,089 older men diagnosed with prostate cancer were used to analyze the association between androgen deprivation therapy, a hormone-suppressing therapy used to treat prostate cancer, and subsequent diagnosis of Alzheimer disease or dementia. Of the men, 62,330 (average age 76) received androgen deprivation therapy within two years of being diagnosed with prostate cancer and 91,759 men (average age 74) didn't have such treatment.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news